A Phase 3 interventional study of Istradefylline in Parkinson's Disease, sponsored by Kyowa Kirin, Inc.. Terminated at 1 site in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2024-05-17.
Sponsored by Kyowa Kirin, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing istradefylline in Parkinson Disease — none open to participants now, none under way, none of them phase 3. istradefylline · Parkinson Disease.
Among the 20 studies testing istradefylline in Parkinson Disease, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2005, is one of 10 in phase 3, and was the 2nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →None of the 20 studies testing istradefylline in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
istradefylline: first FDA approval 2019 (NOURIANZ). What it is approved for, and how studies give it, is on its page →
Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 11 · Phase 4 1
First in 2000; this study’s year is marked. 5 started in 2005.
This study's enrollment of 504 is above the median of 40 across 3,358 interventional studies indexed under Parkinson Disease.
Median enrollment 239 across the 19 interventional studies. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 5 most frequent:
This study is registered under Kyowa Kirin, Inc., one of the names counted as Kyowa Kirin Co., Ltd.. Under that name alone:
Kyowa Kirin, Inc. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
28 studies in Parkinson Disease by Kyowa Kirin Co., Ltd.: none open now, none under way, none of them phase 3. Of 28 finished, 3 (11%) have results posted.
Among the 28 studies in Parkinson Disease by Kyowa Kirin Co., Ltd., this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2005, is one of 12 in phase 3, and was the 1st registered.
Kyowa Kirin Co., Ltd.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing istradefylline in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kyowa Kirin Co., Ltd.’s 28 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind study 6002-INT-001 are eligible to enter into this long-term open safety study with a starting istradefylline dose of 20 or 40mg per day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
Drug: Istradefylline
Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Also known as: KW-6002
Safety as Measured by Adverse Events
Investigation of the long-term tolerability and safety of istradefylline
Time frame: Every 2 months up to 32 months
73 study centers in the US and Canada recruited subjects from the initiation date (28 October 2005). Patients who had previously participated in Study 6002-INT-001 were eligible to participate in this follow-on safety study,and hence had been taking istradefylline for at least a year.
| Milestone | Single Arm |
|---|---|
| Started | 504 |
| Completed | 0 |
| Not completed | 504 |
| Withdrew: Withdrawal by subject | 38 |
| Withdrew: Adverse event | 73 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Lack of efficacy | 27 |
| Withdrew: Not including due to early termination | 37 |
| Withdrew: Study termination by sponsor | 323 |
Investigation of the long-term tolerability and safety of istradefylline
| participants | Single Arm |
|---|---|
| Safety as Measured by Adverse Events | 477 |
Collected over Dosing to end of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Arm | — | 201/503 (40%) | 276/503 (54.9%) |
| Event | Single Arm |
|---|---|
| Parkinson's diseaseNervous system disorders | 51/503 |
| Confusional statePsychiatric disorders | 10/503 |
| AccidentInjury, poisoning and procedural complications | 9/503 |
| SyncopeNervous system disorders | 8/503 |
| Hip fractureInjury, poisoning and procedural complications | 8/503 |
| PneumoniaInfections and infestations | 8/503 |
| Localised osteoarthritisMusculoskeletal and connective tissue disorders | 6/503 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 6/503 |
| Myocardial infarctionCardiac disorders | 6/503 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 5/503 |
| Event | Single Arm |
|---|---|
| Parkinson's diseaseNervous system disorders | 151/503 |
| DyskinesiaNervous system disorders | 136/503 |
| AccidentInjury, poisoning and procedural complications | 102/503 |
| HallucinationPsychiatric disorders | 69/503 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 63/503 |
| DepressionPsychiatric disorders | 54/503 |
| ConstipationGastrointestinal disorders | 49/503 |
| InsomniaPsychiatric disorders | 49/503 |
| Urinary tract infectionInfections and infestations | 47/503 |
| Back painMusculoskeletal and connective tissue disorders | 46/503 |
503 subjects took at least 1 dose of study drug
| Age, Categorical(Participants) | Single Arm |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 244 |
| >=65 years | 259 |
| Age, Continuous(years) | Single Arm |
|---|---|
| Mean | 64.5 ± 8.98 |
| Sex: Female, Male(Participants) | Single Arm |
|---|---|
| Female | 155 |
| Male | 348 |
| Region of Enrollment(participants) | Single Arm |
|---|---|
| United States | 401 |
| Canada | 102 |
The record gives a start of Oct 2005, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 4 years 9 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Istradefylline